Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 189.55

+3.5%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Flagrante Delictu who wrote (13052)	1/7/1998 7:21:00 AM
From: Henry Niman	Read Replies (2) of 32384

Bernie, You are correct about Targretin & psoriasis. LGND is deciding on which compounds to move to the next stage of the registration process and they want to see Targretin data on psoriasis before they decide which compound to us in the Phase III trial. I think that there is a somewhat analogous situation with Targretin and Panretin activity against several tumor types. I expect that press releases will be tied to advancement to pivotal trials, and that will dtermine the timing and order of announcements, which may be somewhat dependent on discussions with the FDA. A good example could be Panretin in Phase III trials for APL. I expected a simple expansion of the Phase II trial, but LGND is actually doing a Panretin/Vessinoid comparision. I'm not sure if there is a second Phase III trial (possibly using patients who have failed prior therapies since the current one targets new patients), and I'm not sure if the FDA suggested the comparitive trial, or LGND chose the tougher end point to show the superiority of their approach (in which they should have a huge lead in the side effects area).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next